Companies › Merck & Co. (MSD)
69 active drug programs in 1148 registered trials: 669 Phase 2, 253 Phase 1, 201 Phase 3, 25 Phase 4; Oncology, Other, Infectious disease, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sotatercept (MK-7962) Inhibin beta A chain inhibitor | INHBA | Phase 4 | Pulmonary Arterial Hypertension; Hypertension, Pulmonary; Pulmonary Arterial Hypertension PAH; Eisenmenger Syndrome … | Apr 2028 |
| Pembrolizumab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Melanoma; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Head and Neck Neoplasms … | Nov 2026 |
| Enlicitide Decanoate (MK-0616) PCSK9 inhibitor | PCSK9 | Phase 3 | Hyperlipidemia; Hypercholesterolemia; Arteriosclerosis; Lipoprotein(a) … | Dec 2026 |
| Belzutifan (MK-6482) Endothelial PAS domain-containing protein 1 inhibitor | EPAS1 | Phase 3 | Carcinoma, Renal Cell; Renal Cell Carcinoma; Von Hippel-Lindau Disease; Neoplasm Malignant … | Dec 2026 |
| Sacituzumab Govitecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Cancer; Non-small Cell Lung Cancer (NSCLC); Breast Neoplasms … | Jan 2027 |
| 9-valent human papillomavirus (9vHPV) vaccine (Types 6, 11, 16, 18, 31, 33, 45, Aluminum-adjuvanted recombinant protein vaccine containing virus-like particles of recombi | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Papillomavirus Infections; Genital Warts | Jan 2027 |
| Nemtabrutinib (MK-1026) Bruton's tyrosine kinase inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Hematologic Malignancies; Severe Renal Impairment … | Feb 2027 |
| Lenvatinib (MK-7902) Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma … | Feb 2027 |
| Tulisokibart Humanized monoclonal antibody that binds tumor necrosis factor-like cytokine 1A (TL1A) | TL1A | Phase 3 | Crohn's Disease; Ulcerative Colitis; Crohn Disease; Psoriatic Arthritis … | Feb 2027 |
| Quavonlimab CTLA-4 inhibitor | CTLA4 | Phase 3 | Carcinoma, Renal Cell | Apr 2027 |
| Intismeran autogene (mRNA-4157, V940) Autologous tumor-infiltrating lymphocyte (TIL) therapy with mRNA-4157 personalized neoanti | – | Phase 3 | Melanoma; Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Renal Cell Carcinoma … | Apr 2027 |
| Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms … | May 2027 |
| EV (Enfortumab Vedotin) Nectin-4 binding agent; Tubulin inhibitor | NECTIN4, Tubulin | Phase 3 | Urinary Bladder Cancer, Muscle-invasive; Bladder Cancer; Metastatic Urothelial Carcinoma | May 2027 |
| Favezelimab Lymphocyte activation gene 3 protein inhibitor | LAG3 | Phase 3 | Solid Tumors; Metastatic Urothelial Carcinoma; Small Cell Lung Carcinoma | May 2027 |
| Suvorexant (MK-4305) Orexin receptor antagonist | HCRTR2, HCRTR1 | Phase 3 | Insomnia; Alcohol Use Disorder (AUD); Suicide Risk; Autism … | Jun 2027 |
| Bomedemstat (MK-3543) Lysine-specific histone demethylase 1 inhibitor | KDM1A | Phase 3 | Essential Thrombocythemia; Thrombocythemia, Essential; Polycythemia Vera; Acute Myeloid Leukemia | Jul 2027 |
| MK-8527 HIV-1 entry inhibitor | – | Phase 3 | Human Immunodeficiency Virus (HIV); Healthy | Jul 2027 |
| Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLG, RT | Phase 3 | HIV-1 Infection; HIV Infection; Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Aug 2027 |
| Cirmtuzumab (MK-2140) Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor | ROR1 | Phase 3 | Diffuse Large B-Cell Lymphoma; DLBCL; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large B-Cell, Diffuse (DLBCL) … | Sep 2027 |
| Opevesostat (MK-5684) 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor blocking steroid hormone synt | HSD11B1, AR | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic; Malignant Neoplasm; Prostatic Neoplasms, Castration-Resistant … | Nov 2027 |
| V503 9-valent HPV L1 virus-like particle vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58) | – | Phase 3 | Papillomavirus Infections | Dec 2027 |
| Calderasib (MK-1084) KRAS G12C inhibitor | KRAS | Phase 3 | Non-small Cell Lung Cancer; Colon Adenocarcinoma; Malignant Neoplasm; Neoplasm Malignant … | Jan 2028 |
| Patritumab Deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor | ERBB3, TOP1 | Phase 3 | Breast Neoplasms; Non-small Cell Lung Cancer; Gastroesophageal Junction; Gastrointestinal Cancer … | May 2028 |
| Ifinatamab Deruxtecan (I-DXd) | – | Phase 3 | Prostate Cancer; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Cancer; Malignant Neoplasm … | Jun 2028 |
| Doravirine Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator | RT, POLA2, POLG | Phase 3 | HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV … | Jul 2028 |
| MK-8748 | – | Phase 3 | Diabetic Retinopathy | Oct 2028 |
| R-DXD (Raludotatug deruxtecan, MK-5909, DS-6000a) | – | Phase 3 | Ovarian Cancer; Gastrointestinal Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung … | Jan 2029 |
| Cetuximab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Colon Adenocarcinoma; Lung Neoplasm Malignant | Mar 2029 |
| Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 3 | Pulmonary Disease, Chronic Obstructive | Apr 2029 |
| Molnupiravir (MK-4482, LAGEVRIO®) Nucleoside analog inhibitor of viral RNA-dependent RNA polymerase (RdRp) | RDRP | Phase 3 | Coronavirus Disease (COVID-19); Respiratory Syncytial Virus; COVID-19; Dengue | Jan 2031 |
| V181 Live attenuated dengue virus vaccine | – | Phase 3 | Healthy | Oct 2031 |
| Ulonivirine (MK-8507) | – | Phase 2 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection; Healthy | Jan 2027 |
| Posaconazole (MK-5592) Cytochrome P450 51 inhibitor | CYP51A1 | Phase 2 | Invasive Fungal Infection; Posaconazole; Breast Cancer; Hematologic Malignancy | Mar 2027 |
| MK-4830 | – | Phase 2 | Colorectal Cancer; Esophageal Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Jun 2027 |
| MK-7262 Lp(a)-lowering agent | – | Phase 2 | Lipoprotein(a) | Oct 2027 |
| MK-8690 (PRA052) | – | Phase 2 | Colitis Ulcerative | Oct 2027 |
| MK-2010 Immune checkpoint inhibitor | – | Phase 2 | Malignant Neoplam; Advanced Solid Tumors | Sep 2028 |
| ISL/ULO fixed-dose combination of nucleoside reverse transcriptase translocation inhibitor and non | POLR2A | Phase 2 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Feb 2029 |
| MK-2214 Anti-tau therapeutic - designed to slow tau accumulation and spread in the brain | – | Phase 2 | Early Alzheimer's Disease | Apr 2029 |
| MK-1045 anti-CD19 bispecific antibody (engaging T cells for B-cell acute lymphoblastic leukemia) | CD19 | Phase 2 | Follicular Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukaemia; Systemic Lupus Erythematosus … | Jul 2029 |
| Vericiguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF); Endothelial Dysfunction; Post-COVID ME/CFS … | Aug 2029 |
| Frespaciguat (MK-5475) Soluble guanylate cyclase (sGC) stimulator | GUCY1A1, GUCY1B1 | Phase 2 | Pulmonary Hypertension | Oct 2029 |
| Miransertib (MK-7075) Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS); Proteus Syndrome | Feb 2030 |
| MK-4646 HIV-1 treatment agent | – | Phase 1 | Healthy | Nov 2026 |
| V540D HPV vaccine targeting multiple HPV types including those covered by GARDASIL®9 plus additi | – | Phase 1 | Healthy | Nov 2026 |
| MK-4082 GLP-1 receptor agonist | GLP1R | Phase 1 | Healthy | Dec 2026 |
| Infinatamab Deruxtecan (I-DXd, MK-2400) HER2-targeting antibody-drug conjugate | ERBB2 | Phase 1 | Oesophageal Squamous Cell Carcinoma; Small Cell Lung Cancer Extensive Stage; Esophageal Squamous Cell Carcinoma | Jun 2027 |
| V118E Pneumococcal polysaccharide conjugate vaccine | – | Phase 1 | Healthy | Jul 2027 |
| MK-3120 Intravesical immunotherapy | – | Phase 1 | Bladder Cancer; Advanced Solid Tumors; Urothelial Carcinoma | Jul 2027 |
| Vibostolimab | – | Phase 1 | Metastatic Castration-Resistant Prostate Cancer; Carcinoma, Non-Small-Cell Lung | Oct 2027 |
| MK-8644 | – | Phase 1 | Psoriasis | Dec 2027 |
| Letermovir (MK-8228) DNA terminase inhibitor | UL89 | Phase 1 | Cytomegalovirus Prophylaxis; Kidney Transplant; CMV; Cytomegalovirus Infections … | Apr 2028 |
| V132 Formulation 1 Pneumococcal vaccine | – | Phase 1 | Healthy | May 2028 |
| V540B Multi-type HPV vaccine with adjuvant | – | Phase 1 | Healthy | May 2028 |
| MK-0472 | – | Phase 1 | Metastatic Solid Tumors | Jun 2028 |
| V350A EBV vaccine | – | Phase 1 | Healthy | Jul 2028 |
| V350B EBV vaccine | – | Phase 1 | Healthy | Jul 2028 |
| V175 RSV multivalent vaccine | – | Phase 1 | Lower Respiratory Tract Infection | Aug 2028 |
| V175A RSV multivalent vaccine | – | Phase 1 | Lower Respiratory Tract Infection | Aug 2028 |
| MK-1045 Immunotherapy for B-cell lymphoma | – | Phase 1 | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma; Acute Lymphoblastic Leukemia | Sep 2028 |
| V118C pneumococcal polysaccharide conjugate vaccine | – | Phase 1 | Pneumococcal Infection | Oct 2028 |
| Gocatamig (MK-6070) T-cell engager | – | Phase 1 | Small Cell Lung Cancer; Small Cell Lung Cancer Extensive Stage | Feb 2029 |
| MK-8294 | – | Phase 1 | Metastatic Neoplasm | Jul 2029 |
| MK-4884 | – | Phase 1 | Malignant Neoplasm | Oct 2029 |
| MK-4716 | – | Phase 1 | Malignant Neoplasm | Dec 2030 |
| Boserolimab TIM-3 inhibitor | HAVCR2 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Feb 2032 |
| MK-0482 Toll-like receptor agonist | – | Phase 1 | Carcinoma, Non-Small-Cell Lung | Feb 2032 |
| MK-1403 | – | Phase 1 | Healthy | – |
| MK-1484 | – | Phase 1 | Advanced or Metastatic Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02362594 | Pembrolizumab | Phase 3 | Melanoma | Oncology | Jan 2018 |
| NCT02998268 | Pembrolizumab | Phase 2 | Esophageal Adenocarcinoma | Oncology | Feb 2021 |
| NCT03591276 | Pembrolizumab | Phase 1 | Metastatic Breast Cancer | Oncology | Apr 2021 |
| NCT02641093 | Pembrolizumab | Phase 2 | Head and Neck Cancer | Oncology | Apr 2021 |
| NCT03468218 | Pembrolizumab | Phase 2 | Metastatic Head and Neck Carcinoma | Oncology | May 2022 |
| NCT02743819 | Pembrolizumab | Phase 2 | Melanoma | Oncology | Jun 2022 |
| NCT02852655 | Pembrolizumab | Phase 1 | Brain Cancer | Oncology | Jun 2022 |
| NCT03698019 | Pembrolizumab | Phase 2 | Acral Lentiginous Melanoma | Oncology | Sep 2022 |
| NCT03753243 | Pembrolizumab | Phase 2 | Prostate Cancer | Oncology | Sep 2022 |
| NCT02752685 | Pembrolizumab | Phase 2 | Breast Cancer | Oncology | Dec 2022 |
| NCT04956692 | Pembrolizumab | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Apr 2023 |
| NCT04956692 | Pembrolizumab | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Apr 2023 |
| NCT04014530 | Pembrolizumab | Phase 1 | Colorectal Cancer | Oncology | Jun 2023 |
| NCT02965716 | Pembrolizumab | Phase 2 | Advanced Melanoma | Oncology | Jun 2023 |
| NCT03425643 | Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | Oncology | Jul 2023 |
| NCT04857164 | Pembrolizumab | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Aug 2023 |
| NCT03385226 | Pembrolizumab | Phase 2 | Cutaneous T Cell Lymphoma | Oncology | Sep 2023 |
| NCT03732950 | Pembrolizumab | Phase 2 | Recurrent Fallopian Tube Carcinoma | Oncology | Dec 2023 |
| NCT03813836 | Pembrolizumab | Phase 2 | Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Jan 2024 |
| NCT04195750 | Belzutifan (MK-6482) | Phase 3 | Carcinoma, Renal Cell | Oncology | Apr 2024 |
| NCT03488667 | Pembrolizumab | Phase 2 | Gastro Esophageal Junction Cancer | Oncology | Apr 2024 |
| NCT05824468 | Lenvatinib (MK-7902) | Phase 2 | Cervical Cancer | Oncology | Jul 2024 |
| NCT03813394 | Pembrolizumab | Phase 1 | Locally Recurrent Cancer | Oncology | Jul 2024 |
| NCT04009967 | Pembrolizumab | Phase 2 | Prostate Cancer | Oncology | Sep 2024 |
| NCT03971045 | Pembrolizumab | Phase 2 | Breast Cancer | Oncology | Dec 2024 |
| NCT03971045 | Pembrolizumab | Phase 2 | Breast Cancer | Oncology | Dec 2024 |
| NCT06482086 | Lenvatinib (MK-7902) | Phase 2 | Locally Advanced Thyroid Gland Carcinoma | Oncology | Dec 2024 |
| NCT04287829 | Pembrolizumab | Phase 2 | Mesotheliomas Pleural | Oncology | Dec 2024 |
| NCT04287829 | Lenvatinib (MK-7902) | Phase 2 | Mesotheliomas Pleural | Oncology | Dec 2024 |
| NCT04777084 | Lenvatinib (MK-7902) | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2024 |
| NCT05033756 | Pembrolizumab | Phase 2 | Malignant Neoplasm of Breast | Oncology | Jan 2025 |
| NCT03474497 | Pembrolizumab | Phase 1 | Non Small Cell Lung Cancer | Oncology | Apr 2025 |
| NCT04895722 | Pembrolizumab | Phase 2 | Colorectal Cancer | Oncology | May 2025 |
| NCT04895722 | MK-4830 | Phase 2 | Colorectal Cancer | Oncology | May 2025 |
| NCT05252429 | Pembrolizumab | Phase 2 | Effect of Drug | Oncology | May 2025 |
| NCT04340258 | Pembrolizumab | Phase 1 | HNSCC | Oncology | Jun 2025 |
| NCT05745350 | Pembrolizumab | Phase 2 | Small Cell Lung Cancer Extensive Stage | Oncology | Jun 2025 |
| NCT05113186 | Lenvatinib (MK-7902) | Phase 2 | Hepatocellular Carcinoma | Oncology | Jun 2025 |
| NCT03240211 | Pembrolizumab | Phase 1 | PTCL | Oncology | Jul 2025 |
| NCT05824481 | Lenvatinib (MK-7902) | Phase 2 | Endometrial Cancer | Oncology | Jul 2025 |
| NCT05010681 | Lenvatinib (MK-7902) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Aug 2025 |
| NCT06880029 | Pembrolizumab | Phase 1 | Triple Negative Breast Cancer (TNBC) | Oncology | Sep 2025 |
| NCT04030455 | Pembrolizumab | Phase 2 | Laryngeal Squamous Cell Carcinoma | Oncology | Sep 2025 |
| NCT04869137 | Pembrolizumab | Phase 2 | Merkel Cell Carcinoma | Oncology | Sep 2025 |
| NCT04869137 | Lenvatinib (MK-7902) | Phase 2 | Merkel Cell Carcinoma | Oncology | Sep 2025 |
| NCT04373642 | Pembrolizumab | Phase 2 | Head and Neck Cancer | Oncology | Oct 2025 |
| NCT05595447 | Pembrolizumab | Phase 2 | Hodgkin Lymphoma | Oncology | Oct 2025 |
| NCT05098847 | Lenvatinib (MK-7902) | Phase 2 | Liver Metastasis | Oncology | Oct 2025 |
| NCT04513626 | Doravirine | Phase 2 | HIV Infections | Infectious disease | Oct 2025 |
| NCT02778685 | Pembrolizumab | Phase 2 | Metastatic Breast Carcinoma | Oncology | Oct 2025 |
| NCT05508737 | Pembrolizumab | Phase 1 | Gastric and Gastroesophageal Junction Adenocarcinoma | Oncology | Nov 2025 |
| NCT04825990 | Pembrolizumab | Phase 2 | Nasopharyngeal Carcinoma | Oncology | Nov 2025 |
| NCT03512405 | Pembrolizumab | Phase 1 | CD19 Positive | Oncology | Nov 2025 |
| NCT03029403 | Pembrolizumab | Phase 2 | Advanced Cancer | Oncology | Dec 2025 |
| NCT04547504 | Pembrolizumab | Phase 3 | Non-small-cell Lung Cancer | Oncology | Dec 2025 |
| NCT04547504 | Pembrolizumab | Phase 3 | Non-small-cell Lung Cancer | Oncology | Dec 2025 |
| NCT06032845 | Lenvatinib (MK-7902) | Phase 2 | Solid Tumor, Adult | Oncology | Dec 2025 |
| NCT03717623 | Posaconazole (MK-5592) | Phase 4 | Posaconazole | Infectious disease | Dec 2025 |
| NCT06230471 | Pembrolizumab | Phase 2 | Biliary Tract Neoplasms Immunotherapy | Oncology | Dec 2025 |
| NCT04592211 | Pembrolizumab | Phase 1 | Gastric Cancer Stage IV | Oncology | Dec 2025 |
The 60 nearest readouts of 1148 trials; the rest in the app.
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.